Related Experiment Video
Updated: Aug 18, 2026

Mouse- and Human-derived Primary Gastric Epithelial Monolayer Culture for the Study of Regeneration
Published on: May 7, 2018
Chief cell mass after short-term ranitidine treatment for duodenal ulcer
1Department of Gastroenterology, San Martino Hospital, Genova, Italy.
Abstract:
The chief cell mass and the parietal cell mass were evaluated in endoscopically obtained biopsy specimens of fundic mucosa from 15 duodenal ulcer patients before and after ranitidine treatment. Patients were given ranitidine, 300 mg/day, for 8 weeks. Chief cell mass and parietal cell mass were expressed respectively by a "zymogenous index" (ZI) and a "parietal index" (PI), obtained by multiplying the number of cells per mm2 by the thickness of the glandular layer. From the results of this study it would appear that, in patients with duodenal ulcer, treatment with ranitidine at a dose of 300 mg/day for 8 weeks results in a significant increase in parietal cell mass and a decrease in chief cess mass.
More Related Videos
07:05Important Endpoints and Proliferative Markers to Assess Small Intestinal Injury and Adaptation using a Mouse Model of Chemotherapy-Induced Mucositis
Published on: May 12, 2019
03:05Establishment and Evaluation of a Risk Prediction Model for Pathological Escalation of Gastric Low-Grade Intraepithelial Neoplasia
Published on: February 16, 2024
Related Concept Videos
Pathophysiology of Peptic Ulcer Disease: Injurious Factors
In the antrum region, G cells secrete the gastrin hormone that binds to gastrin-cholecystokinin-B (CCK2) receptors on parietal and enterochromaffin-like (ECL) cells in the fundic glands. Simultaneously, the vagus nerve releases acetylcholine, which binds to M3...
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
Peptic Ulcer Disease V: Surgical Management and Nursing Care
Surgical Interventions for Peptic Ulcer Disease
Gastritis II: Pathophysiology